Impax Settles With Daiichi, Genzyme Over Generic Welchol

Law360, New York (June 30, 2011, 12:27 PM EDT) -- Impax Laboratories Inc. said Thursday it had resolved patent litigation brought by Daiichi Sankyo Inc and Genzyme Corp. in Delaware over cholesterol drug Welchol, striking a deal that will allow Impax to launch a generic version in 2015.

As part of the settlement, Impax said it would be permitted to launch a generic Welchol tablet on March 2, 2015 — or earlier under certain circumstances. The settlement also allows for a release of generic Welchol in two oral suspension strengths, 1.875 grams per packet and 3.75...
To view the full article, register now.